

A biopharmaceutics classification scheme for the development of new drugs

Dissertation
zur Erlangung des Doktorgrades
der Naturwissenschaften

Vorgelegt beim Fachbereich
Biochemie, Chemie und Pharmazie
der Johann Wolfgang Goethe-Universität
in Frankfurt am Main

von
Marc Lindenberg
aus Groß-Gerau

Frankfurt am Main, 2007
(D 30)

Vom Fachbereich Biochemie, Chemie und Pharmazie
der Johann Wolfgang Goethe-Universität als Dissertation angenommen.

Dekan:..... Prof. Dr. Harald Schwalbe

1. Gutachter:..... Prof. Dr. Jennifer B. Dressman

2. Gutachter:..... Prof. Dr. Gisbert Schneider

Datum der Disputation:..... 28.11.2007

Berichte aus der Pharmazie

Marc Lindenberg

**A biopharmaceutics classification scheme
for the development of new drugs**

Shaker Verlag
Aachen 2008

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at <http://dnb.d-nb.de>.

Zugl.: Frankfurt am Main, Univ., Diss., 2007

Copyright Shaker Verlag 2008

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers.

Printed in Germany.

ISBN 978-3-8322-6927-2

ISSN 0945-0939

Shaker Verlag GmbH • P.O. BOX 101818 • D-52018 Aachen

Phone: 0049/2407/9596-0 • Telefax: 0049/2407/9596-9

Internet: www.shaker.de • e-mail: info@shaker.de

Danksagung

Die vorliegende Arbeit entstand im Rahmen meiner Tätigkeit als wissenschaftlicher Angestellter am Institut für pharmazeutische Technologie der Johann Wolfgang Goethe-Universität Frankfurt am Main.

Besonders danken möchte ich meiner Doktormutter, Frau Professor Jennifer B. Dressman für die hervorragende wissenschaftliche Betreuung während meiner Zeit am Institut und für die Möglichkeit auf internationalen Kongressen meine Arbeit vorzustellen.

A great thanks goes to Dr. Marcus Brewster and Dr. Jef Peeters from the company of Janssen Pharmaceutica in Beerse, Belgium for supporting my work financially as well as scientifically.

Meinen Eltern danke ich für ihre immerwährende Unterstützung in allen Lebenslagen und für ihre unendliche Geduld, die sie mit mir hatten und immer noch haben.

Weiterhin danke ich den Mitarbeitern des Instituts für pharmazeutische Technologie insbesondere meinen ehemaligen Kollegen der Arbeitsgruppe: Corina Becker, Karen Beltz, Dieter Bischoff, Dr. Matthias Fischbach, Dr. Thomas Fürst, Dr. Alexander Glomme, Marc Hugo, Dr. Ekarat Jantratid, Niels Janssen, Daniel Jünemann, Kevin Kiehm, Murat Kilic, Dr. Sandra Klein, Dr. Christian Leuner, Kathrin Nollenberger, Anna Christine Petereit, Frank Seiler, Dr. Erika Stippler, Dr. Martin Wunderlich und Thomas Zöller.

Spezieller Dank geht an Dr. Alexander Bootz, Christiane Fürst und Dr. Kristina Leuner für wertvolle Diskussionen während und nach meiner Zeit am Institut.

Table of Contents

1	Introduction	1
1.1	Solubility of solids in fluids	3
1.1.1	Enthalpy of mixing	4
1.1.2	Entropy of mixing	6
1.1.3	Free energy of mixing	6
1.1.4	Factors influencing solubility	7
1.1.4.1	Substance-related factors	7
1.1.4.2	Environment related - GI Tract	9
1.2	The Biopharmaceutics Classification Scheme (BCS)	18
1.2.1	The current BCS	18
1.2.2	Proposed changes to the BCS	21
1.2.3	BCS for development.....	23
1.3	Methods to enhance the solubility of substances.....	27
2	Aims of the work	35
3	Material and Methods.....	37
3.1	Criteria for the classification of the WHO substances in the BCS scheme..	37
3.2	Standard materials.....	40
3.3	Standard media	43
3.3.1	Buffer solutions to simulate the usual (low pH) gastric conditions	43
3.3.2	Buffer solutions to simulate the gastric conditions under elevated pH.	43
3.3.3	Buffer solutions to simulate the small intestine	44
3.4	Filter testing	46
3.4.1	Substances.....	47
3.4.1.1	Chemical structures.....	48
3.4.1.2	Physicochemical properties of substances used for filter adsorption studies	49
3.4.1.3	Batches used and origin of the substances used for filter adsorption studies	49
3.4.1.4	Indications and maximum daily doses of substances used for filter adsorption studies	50
3.4.2	Filters used in adsorption studies	50

Table of Contents

3.4.3	Media used in filter adsorption studies.....	51
3.4.4	Methodology of testing filters for adsorption	51
3.4.5	UV analysis of solutions and filtrates in the filter adsorption studies....	53
3.5	Solubility and logP measurement	53
3.5.1	Substances examined by the different methods	53
3.5.1.1	Substances examined with the traditional shake-flask method only 54	
3.5.1.2	Substances examined with the traditional shake-flask method and the miniaturized method	57
3.5.1.3	Substances examined only with the miniaturized method (additional weak bases).....	62
3.5.2	Specific materials for solubility and logP measurements	66
3.5.3	Media used for solubility determinations.....	66
3.5.3.1	Media used only with the traditional shake-flask method.....	67
3.5.3.2	Media used with both the traditional shake-flask method and the miniaturised method	67
3.5.3.3	Media used only with the miniaturised method	69
3.5.4	Methodology of the solubility and logP experiments	70
3.5.4.1	Traditional shake-flask method for solubility	71
3.5.4.2	Miniaturized shake-flask method for solubility	71
3.5.4.3	Extrapolating solubility using the “dilution method”	73
3.5.4.4	LogP determination	74
3.5.5	HPLC and UV analysis	75
3.5.5.1	UV analysis.....	75
3.5.5.2	HPLC analysis	75
3.6	Solubility and logP calculation	79
3.6.1	Computational calculation.....	79
3.6.2	LogD and pH-dependent solubility calculations	79
3.6.3	Calculation of the solubility in FaSSIF and FeSSIF	81
4	Results	83
4.1	BCS classification of the substances on the WHO EML	83
4.1.1	Modified classification criteria for development purposes.....	93
4.2	Filter testing	99

4.3	Solubility experiments	107
4.3.1	Solubilities of aciclovir, allopurinol and diazepam	107
4.3.1.1	Aciclovir	107
4.3.1.2	Allopurinol.....	108
4.3.1.3	Diazepam	108
4.3.2	Solubilities of the Janssen substances	109
4.3.2.1	Comparison traditional and miniaturized method.....	109
4.3.2.2	Solubility profiles of Jan A-H.....	111
4.3.2.3	Maximum dissolvable dose of the Janssen compounds in media simulating the small intestine.....	124
4.3.3	Substances measured only with the miniaturised method	125
4.3.3.1	Amiodarone hydrochloride.....	125
4.3.3.2	Cinnarizine.....	126
4.3.3.3	Diazepam	127
4.3.3.4	Dipyridamole.....	127
4.3.3.5	Miconazole nitrate	128
4.4	In silico calculation of solubilities	129
4.5	Calculation of the solubility in FaSSIF and FeSSIF	132
4.5.1	Calculations using the formula developed by Glomme et al.	132
4.5.1.1	Glomme method	133
4.5.1.2	Estimation of solubility in biorelevant media from the solubility in simple buffer solution.....	140
4.5.2	Improving the predictive capability of the formula for poorly soluble weak bases	147
4.5.2.1	FaSSIF	149
4.5.2.2	FeSSIF	156
4.5.3	Calculated and experimental FaSSIF/FeSSIF data in the context of in vivo data.....	162
4.5.3.1	Fasted state	163
4.5.3.2	Fed state.....	164
5	Discussion	167
5.1	BCS classification of the orally available substances on the WHO EML ..	167
5.2	Filter testing	169

Table of Contents

5.3	Predictions of the solubility in FaSSIF and FeSSIF	170
5.3.1	Experimentally determined solubility in water as calculational basis ..	170
5.3.2	Experimentally determined solubility in blank FaSSIF and blank FeSSIF as the calculational basis for the Glomme equation	171
5.3.3	Differential micellar penetration (DMP) approach to estimating solubility in biorelevant media	172
5.3.4	Practical considerations in predicting intestinal solubility	175
5.4	Summary of the calculations	177
5.4.1	Proposed method for an experimental approach	177
5.4.2	Proposed method for an in silico approach	177
5.5	Application of recommended method of solubility prediction of poorly soluble substances on the WHO Essential Medicines list	178
5.6	Factors other than composition of small intestinal media in oral bioavailability	179
5.7	Steps for choosing a suitable candidate for an oral formulation	180
6	Summary	183
7	Zusammenfassung	187
8	Appendix	193
9	Literature	201
10	Curriculum vitae	207
11	Publications	209
11.1	Articles	209
11.2	Poster presentations / Abstracts	209